US › Healthcare

Alx Oncology Holdings (ALXO)

US · Healthcare · Biotechnology

$1.74-1.14%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-18.0M

EPS

$-0.13

EPS estimate

$-0.15

EPS came in at -0.13 against a street estimate of -0.15 — a beat of 13.3%.

Key statistics

Market cap

$268.3M

Forward P/E

0.0

P/B

1.97

Book value

$0.98

EPS (TTM)

$-1.15

52-week high

$2.66

52-week low

$1.02

50-day MA

$2.02

200-day MA

$1.83

Beta

0.40

Analyst view

Analysts rate Alx Oncology Holdings a buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $4.60.

Shareholding

Insiders

0.89%

Institutions

84.59%

Largest institutional holders

Fund	Stake
RA Capital Management, LLC	9.41%
venBio Partners LLC	9.32%
Redmile Group, LLC	5.35%
Blackstone Inc	4.21%
Driehaus Capital Management LLC	4.15%
TCG Crossover Management, LLC	4.09%
Vanguard Capital Management, LLC	3.02%
Marshall Wace Asset Management Ltd	2.72%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Alx Oncology Holdings — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.